Health & wellbeing 2016: health news, features and resources from around the web
Researchers, to date, have been unable to establish whether the antiseptic anti-bacterial drugs like Nastrozole and Propofol are effective in resisting the different oicron verma peptide variants, which produce huge amounts of pain, itching and swelling in healthy people and can develop into serious infections in germs sensitive to them.
The Danish and Danish Avian Medicines Agency (KPT/CMA) study, carried out in collaboration with Denmark’s Kreditførnet Zørein, involved treating more than 1,200 people from across the world with Omicron, carbapenem, anti-cytotoxic enzymes or Naxalone for two weeks. Those treated with Naxalone developed distinct body chemistry and recorded significantly more serious infections than those treated with other anti-bacterial and preventative treatments such as antibiotics.
Additionally, the study showed that people affected by specific Oicron variants have a better chance of thriving in the chronic and post-symptomatic setting, where the immune system is often low.
“Until now, most of the studies used systematic analysis for assessing results, but the current study evaluated the benefit of anti-bacterial and preventative treatments in a large patient population,” says Professor Stine Vansen, who led the Danish study. “We found that anti-bacterial and preventative treatments are not completely effective against the larger subset of patients exposed to the oicron variants.”
The study has so far found a preference for enzymes that have stronger anti-inflammatory properties over those with significantly reduced potency.
Commenting on the study, Professor Vansen said: “This combination of results confirms what my colleagues have observed in studying the small-scale, community-based cohort of people exposed to the oicron variants. Based on this study, it is not yet known how these treatments affect infections in these people, or whether other therapies can help.”
London, 15 August 2018. Photo: Stine van Vansen